Cargando…
Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance
The enthusiasm about successful novel therapeutic strategies in cancer is often quickly dampened by the development of drug resistance. This is true for targeted therapies using tyrosine kinase inhibitors for EGFR or BRAF mutant cancers, but is also an increasingly recognized problem for immunothera...
Autores principales: | Hammerlindl, Heinz, Schaider, Helmut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842196/ https://www.ncbi.nlm.nih.gov/pubmed/29192388 http://dx.doi.org/10.1007/s12079-017-0435-1 |
Ejemplares similares
-
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
por: Torrano, Joachim, et al.
Publicado: (2019) -
Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer
por: Ravindran Menon, Dinoop, et al.
Publicado: (2020) -
Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer
por: Emran, Abdullah Al, et al.
Publicado: (2019) -
Cellular Reprogramming—A Model for Melanoma Cellular Plasticity
por: Granados, Karol, et al.
Publicado: (2020) -
Developmental Plasticity and Cellular Reprogramming in Caenorhabditis elegans
por: Rothman, Joel, et al.
Publicado: (2019)